Understand the source comparison
Epithalon Gene Expression: Mechanism Comparison
Primary Mechanism Direct TERT mRNA upregulation via transcription factor modulation Indirect telomerase activation through oxidative stress reduction SIRT1 activation (epigenetic regulator, indirect effect on telomerase) Epithalon is the only compound with doc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Direct TERT mRNA upregulation via transcription factor modulation
- Indirect telomerase activation through oxidative stress reduction
- SIRT1 activation (epigenetic regulator, indirect effect on telomerase)
- Epithalon is the only compound with documented direct TERT transcriptional upregulation in human cell models
- Gene Expression Breadth
- 70+ genes across circadian, antioxidant, and DNA repair pathways
- Primarily oxidative stress genes; minimal circadian effect
- Primarily metabolic and mitochondrial genes; limited telomerase impact
- Epithalon demonstrates the broadest multi-pathway gene modulation of the three
- Dosage Required for Effect
- 10 μg/mL in vitro; 5–10 mg subcutaneous in human protocols
- 250–1000 mg oral daily (bioavailability ~15%)
- 500–1000 mg oral daily (bioavailability <1%)
- Epithalon achieves measurable gene expression changes at significantly lower doses due to peptide bioavailability
- Duration of Gene Expression Change
- 48–72 hours peak, declines over 7–10 days without repeat dosing
- Sustained only with continuous daily intake
- Epithalon's transient effect requires repeat administration but avoids tolerance seen with continuous low-grade activation
- Regulatory Status
- Research peptide, not FDA-approved for human use
- Dietary supplement (DSHEA, no FDA pre-approval)
- Epithalon is held to higher purity and handling standards as a research compound but lacks clinical approval for therapeutic claims